GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (MEX:PRQR) » Definitions » Cyclically Adjusted PB Ratio

ProQR Therapeutics NV (MEX:PRQR) Cyclically Adjusted PB Ratio : 0.81 (As of Sep. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is ProQR Therapeutics NV Cyclically Adjusted PB Ratio?

As of today (2024-09-24), ProQR Therapeutics NV's current share price is MXN36.00. ProQR Therapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was MXN44.57. ProQR Therapeutics NV's Cyclically Adjusted PB Ratio for today is 0.81.

The historical rank and industry rank for ProQR Therapeutics NV's Cyclically Adjusted PB Ratio or its related term are showing as below:

MEX:PRQR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.42   Med: 0.68   Max: 0.92
Current: 0.63

During the past years, ProQR Therapeutics NV's highest Cyclically Adjusted PB Ratio was 0.92. The lowest was 0.42. And the median was 0.68.

MEX:PRQR's Cyclically Adjusted PB Ratio is ranked better than
69.14% of 606 companies
in the Biotechnology industry
Industry Median: 1.6 vs MEX:PRQR: 0.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ProQR Therapeutics NV's adjusted book value per share data for the three months ended in Jun. 2024 was MXN7.932. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN44.57 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ProQR Therapeutics NV Cyclically Adjusted PB Ratio Historical Data

The historical data trend for ProQR Therapeutics NV's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cyclically Adjusted PB Ratio Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.71

ProQR Therapeutics NV Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.58 0.47 0.71 0.83 0.61

Competitive Comparison of ProQR Therapeutics NV's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, ProQR Therapeutics NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Cyclically Adjusted PB Ratio falls into.



ProQR Therapeutics NV Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

ProQR Therapeutics NV's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=36.00/44.57
=0.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, ProQR Therapeutics NV's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=7.932/129.9100*129.9100
=7.932

Current CPI (Jun. 2024) = 129.9100.

ProQR Therapeutics NV Quarterly Data

Book Value per Share CPI Adj_Book
201409 82.445 99.960 107.147
201412 85.258 99.050 111.821
201503 77.700 99.750 101.193
201506 76.675 100.230 99.380
201509 77.687 100.500 100.421
201512 72.047 99.730 93.850
201603 65.848 100.310 85.279
201606 63.132 100.260 81.802
201609 57.103 100.570 73.762
201612 49.497 100.710 63.848
201703 38.594 101.440 49.426
201706 30.991 101.370 39.716
201709 27.820 102.030 35.422
201712 28.660 101.970 36.513
201803 20.736 102.470 26.289
201806 16.440 103.100 20.715
201809 57.827 103.950 72.268
201812 53.393 103.970 66.714
201903 45.723 105.370 56.372
201906 39.398 105.840 48.358
201909 33.452 106.700 40.729
201912 39.736 106.800 48.334
202003 42.452 106.850 51.614
202006 41.520 107.510 50.171
202009 35.609 107.880 42.881
202012 27.519 107.850 33.148
202103 23.693 108.870 28.272
202106 42.233 109.670 50.027
202109 43.722 110.790 51.267
202112 37.012 114.010 42.174
202203 30.983 119.460 33.693
202206 26.037 119.050 28.412
202209 18.100 126.890 18.531
202212 17.138 124.940 17.820
202303 14.070 124.720 14.655
202306 11.885 125.830 12.270
202309 10.615 127.160 10.845
202312 9.417 126.450 9.675
202403 7.692 128.580 7.772
202406 7.932 129.910 7.932

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ProQR Therapeutics NV  (MEX:PRQR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


ProQR Therapeutics NV Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV Business Description

Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.